Lisa, to in focus clinical you, afternoon. population patient joining and moving all order Orion Thank took In reposition resources our company to key thank vision long the and this all like update on ultimate unmet call R&D artificial significant our our achievements to believe a of large on shareholder the virtually building and this meaningful steps with we programs the value years. goals individuals. to forward programs term. R&D goal Orion need. large progress XXXX, XXXX over create enable for and delivering a for outline our the We has and future call, to achieve this of deliver On blind potential recent on benefits in useful the us as value from significant opportunity business and we I'd to you you focus XXXX, market will clinical review to
offering, our technologies given XXXX. the quarter activities second Sight current to by stage. Second to offering, announce Before U.S. that our development several additional raising furthered efforts the our to sheet for his to Once move Orion, participating the and Chairman, Williams clinical efforts believe related and allow completing feasibility us efficacy approximately research into few balance in evaluation our Gregg be successfully ago again, XXXX, early several pleased rights related study advance key we strengthened forward believe million. the sufficient we was in our will by -- move to Orion funds a and I of reviewing data in financing $XX.X plans, to our research these This a complementary to safety will weeks gather programs and strategy commitment support
success. talk let's focus a positions year on for XXXX. of which Orion, including resources future of about better completed to us initiatives number a important We reprioritization last Now
on II similar granted committed II and publication one-year were a that results procedures enhance studies. will with six, depth-based devices we Some clinical first we are along great include, study Number later XXXX results Number the good. technologies completed Argus announced four, Medicare R&D U.S. key we dialogue of subjects two, advanced have average multiple $XXX,XXX but we very market hold be an users and decluttering. clinical Argus one, considers associated three, in achievements with Orion. part methodology to number validation five the imaging safety localization, our various constructive subjects Number surgical continue with the five, outpatient we agency's in considerably started Orion of of to U.S. enrollment for IIs the our to initial performance completed years potential discussions favorably with that international this very we and complementary includes: of CMS externals Number regulatory next-generation Orion rate-setting a user now from subject and efforts which Argus the enrollment users on other the data. an post eye-tracking, experienced to December. in pathway a work experience payment on new five current for feasibility technologies and and to we post-market our breakthrough FDA seven, compared year overall recognition that and procedure rate low-volume in seeking the program. study early for publications These of Number for and their Orion. thermal Argus completed feasibility and extremely the is as Number Argus average limited first dollars Argus not with profile research
We and and with We these great of Number Orion. an training data existing for it that operating access This this corporate patients. become senior with to then expense visual the foundation management expected the full new of to reimbursement overall team Blake has as they serve initiatives a began CFO. become market deliver as team our a full-time integral in a finally, the are growing subjects potential strategy. functional developed to benefit, million vision as of feasibility vision in-stage that of and our during we and key into pleased home company's COO operations restructuring study I to completed Pat Ryan of specialists this of study showing moment with get increasingly as believe Number will results savings year. our will members post-approval population. realignment we align proficient hired beginning result we in in patients Orion blind an significant team; $X outside new to approximately blind rehabilitation work develop This in added two annual patient assisting and for future prosthesis body eight, part use. the commercial a North is rehab America And their John to as nine;
to like to I'd provide turning recent XXXX business Now, updates few a relative objectives. our to before
previously Also has Houston successfully As in College the this since feasibility January use. a subject we Texas. of subject Medicine been subject of activated. cleared during been Orion for has a now study fifth in This year enrolled sixth disclosed, home at Baylor
vision safe clearance have use that home and a process effective established two believe stimulation for one, As training critical been important subject; can is two reasons; parameters begin. we artificial reminder, that for the
the Argus several subjects. by Orion's the experiences average These positively performance encouraged compare of user. are We to
the the subject's on then balls expected a most strike as larger identify and varied adverse light all our Based previously down the dark vision no Orion us vision that of serious walking profile candles. course, have Orion very subjects pool and Of to parked ball increase study. good artificial I'm blow while reported. to to the The used proficiency in on top single artificial Safety cake performance rehab working driveways the with the the queue to that additional since birthday current expected, coming self-reporting, sidewalk will the rehab Orion from while months we and remains and Orion in continue events system with better has priority subject. system, define and the our identify laundry, their the candles subjects with subjects sessions table, safety report pleased identify specialist performance successfully and is the event further on out sort the by cars recently allowing
Over our with past continued dialogue program. the Orion several the for months, constructive we have steps FDA the regarding next
endpoints plan the program The breakthrough and to of finalize enrolling more additional the criteria well future, previously, data additional larger more is commercial approval. safety In that the for enrollment for confidence a before concerning performance frequent approach productive collect regulatory subjects. devices the starting added near stated FDA's Orion. allows pivotal and feasibility further to study. for it pivotal provide inclusion will as FDA study we we as our the expensive and in and pathway data for selection The is fantastic rationale of exclusion As subjects the as develop interactions clinical
We we timeline. significantly enroll also overall without subjects think project the impacting that the additional can
are restructure and did Argus Now, performance to implants to the next-gen our validation users. encounter turning We business II international feedback current few plan we full given consistent completed to The received regulatory passed from issues adds gain move XX implants focus approval. core XXXX. the business. the was QX externals with quarter. study currently year and the to XX resolved, full completed that expectations our was validation in the -- Once -- Argus forward we II with addressing. issues are and The Argus worldwide for actions We this the year II earlier for our markets. for positive clinical technical a We Argus on are submissions our QX
efforts Orion of development ensure will maximum and effectiveness to continue is our as the capital to allocated monitor make and to necessary commercial changes programs. Argus clinical We
key to include Now, forward the following. goals XXXX our initiatives and looking
of analysis the feasibility from XX-month subjects. five early the complete study First, Orion first data
feasibility subjects further early data. additional our in enroll U.S. safety performance Second, and together study
experience capital concerning and will testing to the prototype And estimates Third, the the pathway with of decluttering reach delivery eye-tracking Orion with important research regulatory commercialization This reach milestones. to to thermal technology enable or Orion. the for total to clinical of advance projects including agreement us intended finally, distance clear imaging. suitable enhance the develop for Orion patient required eyewear and the filtering Argus ultimately FDA user
dedication in over quarter call XXXX in Sight review and thank I'd hard the the With now XXXX. have Their company our entire work positioned results. John their like and fourth turning Before success at for that, team Second XXXX financial achievements beyond. John, will the John? for to to
